Immunartes

Biotech developing vaccines and antibody therapeutics against infectious diseases, with a focus on S. aureus.

Website: https://www.immunartes.com

Cover Block

PUBLIC
Company Immunartes
Tagline Biotech developing vaccines and antibody therapeutics against infectious diseases, with a focus on S. aureus.
Headquarters Chicago, United States
Founded 2017
Stage Pre-Seed
Business Model Other
Industry Deeptech
Technology Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Academic Spinout
Funding Label Undisclosed
Total Disclosed $10.58M (non-dilutive grants)

PUBLIC

Executive Summary

PUBLIC

Immunartes is a preclinical-stage biotech pursuing a preventive vaccine for Staphylococcus aureus, a pathogen responsible for significant hospital-acquired infections and a major driver of antimicrobial resistance, a global health priority that has attracted substantial non-dilutive funding [Immunartes, Dec 2022]. Founded in 2017 by University of Chicago-affiliated scientists, the company is notable for its reliance on grant capital from major public health entities rather than traditional venture equity, a model that de-risks early R&D but may signal a longer, more milestone-driven path to market [Devex]. Its scientific wedge is a proprietary antigen discovery and delivery platform designed to elicit protective immune responses against pathogens that have historically evaded vaccine development, with preclinical data showing protection against both MRSA and MSSA strains [Immunartes].

The founding team, led by CEO Vilasack Thammavongsa and CSO Dominique Missiakas, brings deep academic expertise in microbiology and immunology from the University of Chicago, though their public record does not yet include prior commercial biotech leadership or exits [Crunchbase]. The business model is currently oriented around achieving preclinical and early clinical milestones funded by contracts like the up-to-$10.4 million award from the National Institute of Allergy and Infectious Diseases (NIAID) and non-dilutive funding from the global AMR accelerator CARB-X [Immunartes, Dec 2022] [CARB-X]. Over the next 12-18 months, the key inflection points to watch are the progression of the lead vaccine candidate into formal IND-enabling studies and any shift in capitalization strategy, such as the pursuit of a first institutional equity round to fund clinical trials.

Data Accuracy: YELLOW -- Core product and grant details are confirmed by company and funder announcements; team backgrounds and funding history are partially corroborated by secondary databases.

Taxonomy Snapshot

Axis Classification
Stage Pre-Seed
Business Model Other
Industry / Vertical Deeptech
Technology Type Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Academic Spinout
Funding Undisclosed

Company Overview

PUBLIC

Immunartes is a Chicago-based biotechnology company founded in 2017 by a group of University of Chicago-affiliated scientists and clinicians [Immunartes]. The company's formation was an academic spinout, rooted in decades of research on microbiology, immunology, and infectious diseases conducted at the university [Immunartes]. Its legal entity is Immunartes LLC, and its public narrative consistently frames its mission as developing vaccines and therapeutics against difficult infectious disease targets, with an initial focus on Staphylococcus aureus [Immunartes, Dec 2022].

Key corporate milestones have been tied to securing non-dilutive funding for preclinical development. In December 2017, the company received a grant of $175,000, though the lead source is not publicly specified [Crunchbase, Dec 2017]. A more significant inflection point came in December 2022, when Immunartes announced a contract award of up to $10.4 million from the National Institute of Allergy and Infectious Diseases (NIAID) for the advanced development of its S. aureus vaccine candidate [Immunartes, Dec 2022]. The company has also received non-dilutive funding from the global antimicrobial resistance accelerator CARB-X to support the same lead program [CARB-X].

Data Accuracy: GREEN -- Company website and federal contract announcement corroborate founding and key funding milestones; grant data confirmed by Crunchbase.

Product and Technology

MIXED

Immunartes is developing a vaccine candidate against Staphylococcus aureus infections, a pathogen responsible for a range of conditions from skin infections to life-threatening sepsis. The company's primary technical claim is that its proprietary antigen discovery and delivery platform can elicit protective immune responses against pathogens that have historically been difficult vaccine targets [Immunartes]. Its lead program is designed to target both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains, aiming to prevent colonization and subsequent invasive disease [Immunartes, Dec 2022].

According to the company, the vaccine candidate uses novel antigen combinations and delivery systems, which have shown protection in preclinical models [Immunartes, Dec 2022]. The platform is also described as enabling the development of antibody-based therapeutics, though the S. aureus vaccine is the only program with disclosed non-dilutive funding support [Immunartes] [CARB-X]. The technology is positioned within the global antimicrobial resistance (AMR) initiative, with a focus on reducing hospital-acquired and community infections [CARB-X].

Data Accuracy: GREEN -- Product claims and technology description are confirmed by the company's own publications and a CARB-X funding announcement.

Market Research

PUBLIC The pursuit of a vaccine for Staphylococcus aureus represents a long-standing, high-value target in infectious disease, driven by the clinical and economic burden of antibiotic-resistant infections and the limited efficacy of current prevention strategies.

Market sizing for a prophylactic S. aureus vaccine is not explicitly quantified in Immunartes's public materials or in the captured third-party research. However, the scale of the problem it aims to address is well-documented. The U.S. Centers for Disease Control and Prevention (CDC) categorizes methicillin-resistant Staphylococcus aureus (MRSA) as a serious threat, estimating it causes over 323,000 infections and more than 10,000 deaths annually in the United States, with associated healthcare costs in the billions [CDC]. The broader S. aureus infection market, including both hospital and community settings, is frequently cited in industry analysis as a multi-billion dollar opportunity for a successful preventive intervention, though specific TAM figures for a vaccine are proprietary to commercial research firms. For context, the global market for all bacterial vaccines was valued at approximately $27.5 billion in 2022 and is projected to grow, with vaccines for hospital-acquired infections representing a significant unmet segment [Precedence Research, 2023] (analogous market, source).

Demand drivers are anchored in public health imperatives rather than discretionary spending. The primary tailwind is the accelerating global antimicrobial resistance (AMR) crisis, which has elevated the development of non-antibiotic countermeasures like vaccines to a top priority for government funders and health systems. Organizations like CARB-X and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) explicitly fund projects like Immunartes's to address this gap [CARB-X]. A second driver is the economic pressure on hospitals to reduce costly hospital-acquired infections (HAIs), which face increasing reimbursement penalties and reporting requirements. A vaccine that reduces post-surgical S. aureus infections could align directly with hospital value-based care initiatives.

Adjacent and substitute markets highlight the competitive dynamics for any future product. The most direct substitute is the continued use of antibiotic prophylaxis and treatment, though this is the very practice a vaccine aims to supplant due to resistance concerns. Other adjacent markets include:

  • Decolonization regimens. Current standard of care for high-risk surgical patients often involves topical antimicrobials (e.g., mupirocin) and antiseptic washes to reduce S. aureus carriage, a market served by several generic pharmaceutical companies.
  • Passive immunotherapies. Some companies are developing monoclonal antibody therapies for S. aureus, which would represent a therapeutic rather than preventive approach and target a different, often sicker, patient population.
  • Broad-spectrum vaccines. Platform technologies aiming to protect against multiple bacterial pathogens could eventually compete for the same R&D funding and strategic partnership dollars.

Regulatory and macro forces are predominantly favorable but carry high barriers. The U.S. Food and Drug Administration (FDA) has established pathways for vaccines targeting unmet medical needs, including those for serious bacterial infections, which can facilitate accelerated development. The funding environment from U.S. government agencies like the National Institute of Allergy and Infectious Diseases (NIAID) and Biomedical Advanced Research and Development Authority (BARDA) for antimicrobial resistance is currently robust, as evidenced by Immunartes's own $10.4 million contract [Immunartes, Dec 2022]. However, the path to market remains long, expensive, and fraught with clinical risk, requiring successful Phase 3 trials that demonstrate a significant reduction in invasive disease, a high regulatory hurdle.

Metric Value
Global Bacterial Vaccine Market (2022) 27.5 $B
Estimated Annual U.S. MRSA Infections 323 K

The chart underscores the substantial baseline burden of the target pathogen, situating the opportunity within a large and growing vaccine market. The absence of a segmented TAM for an S. aureus-specific vaccine is typical for early-stage biotechs, where value is derived from addressing a clear, costly problem rather than from a pre-packaged market size.

Data Accuracy: YELLOW -- Market sizing is inferred from analogous reports and public health data; specific TAM/SAM for an S. aureus vaccine is not publicly disclosed by the company or in cited sources. Demand drivers and regulatory context are well-established in public health literature.

Competitive Landscape

MIXED Immunartes operates in a high-stakes, capital-intensive arena where its primary competition comes not from other early-stage startups but from established pharmaceutical giants and a handful of well-funded biotech challengers pursuing the same unmet medical need. The company's current position is defined by its focus on a notoriously difficult pathogen and its reliance on non-dilutive grant funding, a strategy that distinguishes it from many venture-backed peers.

A direct, named competitor comparison is not possible with the current public data, as no specific rival companies are cited in the available sources. This absence itself is a data point, suggesting Immunartes is either in a less crowded niche of preclinical vaccine development or its public profile has not yet risen to a level where it is routinely benchmarked against named peers in industry reports.

Segmenting the competitive map requires looking beyond the company's immediate vicinity. The field for a Staphylococcus aureus vaccine is dominated by large-cap pharmaceutical companies with deep pipelines and commercial infrastructure. Pfizer, for instance, has advanced a bivalent vaccine candidate (PF-06928316) into Phase 2 trials [PUBLIC]. GlaxoSmithKline also has a history of S. aureus vaccine research. These incumbents represent the ultimate benchmark for success, possessing the clinical development expertise and global sales channels that Immunartes lacks. The challenger cohort consists of other biotech firms, some privately held and some public, which may be further along in development. A lack of named competitors in the sources suggests Immunartes is either earlier-stage than these challengers or targeting a distinct antigenic approach they have not prioritized.

Immunartes's defensible edge today rests on its proprietary antigen discovery platform and its strong academic roots at the University of Chicago [Immunartes]. This scientific foundation has been credible enough to secure non-dilutive funding from major public health entities like the National Institute of Allergy and Infectious Diseases (NIAID) and CARB-X [Immunartes, Dec 2022][CARB-X]. This edge is durable insofar as the platform yields protective antigen combinations that are both novel and patentable. However, it is highly perishable. Platform advantages in biotech are frequently leapfrogged by new scientific discoveries, and the company's grant-dependent model could become a liability if the pace of capital-intensive clinical trials outruns the availability of non-dilutive funding. Without a venture equity round to provide a multi-year runway, the company's ability to retain key scientific talent and outpace well-funded competitors is uncertain.

The company's most significant exposure is to the clinical and regulatory risks inherent in vaccine development, compounded by its apparent lack of a commercial or business development leader on the publicly cited team. A named competitor with a more advanced clinical candidate, deeper pockets, and established partnerships with contract research organizations (CROs) could simply outrun Immunartes, regardless of the elegance of its science. Furthermore, the company does not own any channel to market; its future success is entirely dependent on licensing its candidate to a larger player or forming a partnership, a process where it would have limited use if its asset remains in preclinical stages while others advance.

The most plausible 18-month competitive scenario hinges on clinical data and partnership announcements. In a "winner" scenario, Immunartes successfully translates its preclinical results into compelling Phase 1 safety and immunogenicity data, funded by its existing grants. This milestone would allow it to attract a strategic partnership with a mid-tier pharma company seeking to bolster its anti-infective pipeline, validating its platform and providing the capital for a Phase 2 trial. In a "loser" scenario, a competitor like Pfizer reports positive Phase 2 efficacy data for its candidate, effectively raising the regulatory bar and investor expectations for any newcomer. Concurrently, if Immunartes encounters unexpected preclinical toxicity or manufacturing hurdles, its grant funding could prove insufficient to course-correct, causing the program to stall and the company to lose its window of opportunity.

Data Accuracy: YELLOW -- Competitive analysis is inferred from the company's stated focus and general market knowledge, as no direct competitors are named in captured sources. The assessment of large pharma incumbents is based on publicly reported clinical trial pipelines.

Opportunity

PUBLIC The prize for Immunartes is a first-to-market prophylactic vaccine for a major hospital-acquired infection, a product that could command a multi-billion dollar global market and create a new standard of care for surgical and high-risk patient populations.

The headline opportunity is the establishment of a new, reimbursed standard-of-care vaccine for surgical patients and other at-risk populations. A successful S. aureus vaccine would address a persistent, costly, and deadly hospital-acquired infection for which no preventive option currently exists. The plausibility of this outcome is anchored in the company's alignment with major public health priorities, evidenced by its receipt of a $10.4 million contract from the NIAID specifically for advanced vaccine development [Immunartes, Dec 2022]. This level of non-dilutive funding from a leading U.S. biomedical research agency indicates a recognized need and a credible scientific approach, moving the opportunity beyond pure aspiration into a government-backed development pathway.

Growth would likely follow distinct, phased scenarios, each with a clear catalyst.

Scenario What happens Catalyst Why it's plausible
Hospital Formulary Adoption The vaccine is adopted by major hospital networks for pre-surgical administration to high-risk patients, reducing post-operative infections and associated costs. Successful completion of a Phase 3 clinical trial demonstrating efficacy and cost-effectiveness. The global AMR funder CARB-X has already identified the product as a preventive candidate targeting hospital-acquired infections, validating the market need and target population [CARB-X].
National Immunization Program Inclusion The vaccine is incorporated into national immunization schedules for specific high-risk groups (e.g., dialysis patients, military personnel). Positive recommendation from a national advisory committee on immunization practices (e.g., ACIP in the U.S.). The NIAID contract explicitly frames the work as developing a vaccine for "prevention of invasive S. aureus infections," a public health framing consistent with programmatic use [Immunartes, Dec 2022].

Compounding for a successful vaccine candidate is driven by clinical validation and manufacturing scale. A positive pivotal trial result would not only unlock the primary surgical market but also validate the underlying antigen discovery and delivery platform for other difficult bacterial targets. This proof-of-concept could accelerate partnerships or pipeline expansion into other antibiotic-resistant infections, creating a pipeline flywheel. Early evidence of this platform potential is cited in the company's own materials, which describe a proprietary platform designed for historically difficult vaccine targets [Immunartes].

The size of the win can be contextualized by looking at comparable vaccine markets and recent transactions. Pfizer's 20-valent pneumococcal conjugate vaccine, Prevnar 20, generated over $6 billion in global revenue in 2023 [Pfizer Annual Report, 2024]. While S. aureus is a different indication, it underscores the revenue potential for a vaccine addressing a widespread bacterial threat. A more direct, though earlier-stage, comparable is the 2023 acquisition of Affinivax, a bacterial vaccine company, by GSK for up to $3.3 billion, largely on the strength of its pneumococcal vaccine candidate [GSK, May 2022]. If Immunartes's lead program demonstrates strong Phase 2 data, it could attract partnership or acquisition interest at a significant premium, representing a scenario outcome worth hundreds of millions to low billions of dollars (scenario, not a forecast).

Data Accuracy: YELLOW -- Opportunity size and comparables are inferred from public market data; company-specific growth catalysts are supported by cited grant announcements and public health framing.

Sources

PUBLIC

  1. [Immunartes, Dec 2022] Immunartes News | https://www.immunartes.com/uploads/2/6/5/0/26506652/immunartes_news_.pdf

  2. [Devex] ImmunArtes | Devex | https://www.devex.com/organizations/immunartes-140566

  3. [Immunartes] Our Technology | https://www.immunartes.com/our-technology.html

  4. [Crunchbase] ImmunArtes - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/immunartes

  5. [Crunchbase, Dec 2017] Grant - ImmunArtes - 2017-12-06 - Crunchbase Funding Round Profile | https://www.crunchbase.com/funding_round/immunartes-grant--03bcb4f7

  6. [CARB-X] CARB-X funds Immunartes to develop Staphylococcus aureus preventative | https://carb-x.org/carb-x-news/carb-x-funds-immunartes-to-develop-staphylococcus-aureus-preventative/

  7. [CDC] Antibiotic Resistance Threats in the United States, 2019 | https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

  8. [Precedence Research, 2023] Bacterial Vaccines Market Size, Share, Growth Report 2032 | https://www.precedenceresearch.com/bacterial-vaccines-market

  9. [Pfizer Annual Report, 2024] Pfizer Inc. 2023 Financial Report | https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/PFE-2023-Form-10K.pdf

  10. [GSK, May 2022] GSK to acquire Affinivax | https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-affinivax/

Articles about Immunartes

View on Startuply.vc